You are using an outdated browser. For a faster, safer browsing experience, upgrade for free today.

Life & Medical Care

Global and China Urothelial Cancer Drugs Market Size, Status and Forecast 2020-2026

Urothelial carcinoma or transitional cell carcinoma is a malignant neoplasm occurring from urothelium. The disease is the ninth most common malignancy in the world, with approximately 2.5 million patients and 420,000 newly diagnosed cases each year. Bladder transitional cell carcinoma (TCC) accounted for approximately 90% of all urinary cancer cases.
Market growth is largely attributed to factors such as availability of novel drugs, presence of a strong pipeline, rise in incidence of urothelial cancer due to growing geriatric population, unorganized lifestyle, and rising public awareness.
Market Analysis and Insights: Global Urothelial Cancer Drugs Market
The global Urothelial Cancer Drugs market size is projected to reach US$ 2259.7 million by 2026, from US$ 1086.3 million in 2020, at a CAGR of 13.0% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Urothelial Cancer Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Urothelial Cancer Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Urothelial Cancer Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Urothelial Cancer Drugs market.
Urothelial Cancer Drugs Breakdown Data by Type
Chemotherapy
Immunotherapy
Urothelial Cancer Drugs Breakdown Data by Application
Hospitals
Pharmacy
Based on regional and country-level analysis, the Urothelial Cancer Drugs market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
In the competitive analysis section of the report, leading as well as prominent players of the global Urothelial Cancer Drugs market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The following players are covered in this report:
Roche
Merck
Bristol-Myers Squibb
AstraZeneca
Pfizer
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Urothelial Cancer Drugs Market Size Growth Rate by Type: 2020 VS 2026
1.2.2 Chemotherapy
1.2.3 Immunotherapy
1.3 Market by Application
1.3.1 Global Urothelial Cancer Drugs Market Share by Application: 2020 VS 2026
1.3.2 Hospitals
1.3.3 Pharmacy
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Urothelial Cancer Drugs Market Perspective (2015-2026)
2.2 Global Urothelial Cancer Drugs Growth Trends by Regions
2.2.1 Urothelial Cancer Drugs Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Urothelial Cancer Drugs Historic Market Share by Regions (2015-2020)
2.2.3 Urothelial Cancer Drugs Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Urothelial Cancer Drugs Players by Market Size
3.1.1 Global Top Urothelial Cancer Drugs Players by Revenue (2015-2020)
3.1.2 Global Urothelial Cancer Drugs Revenue Market Share by Players (2015-2020)
3.2 Global Urothelial Cancer Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Urothelial Cancer Drugs Revenue
3.4 Global Urothelial Cancer Drugs Market Concentration Ratio
3.4.1 Global Urothelial Cancer Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Urothelial Cancer Drugs Revenue in 2019
3.5 Key Players Urothelial Cancer Drugs Area Served
3.6 Key Players Urothelial Cancer Drugs Product Solution and Service
3.7 Date of Enter into Urothelial Cancer Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Urothelial Cancer Drugs Breakdown Data by Type (2015-2026)
4.1 Global Urothelial Cancer Drugs Historic Market Size by Type (2015-2020)
4.2 Global Urothelial Cancer Drugs Forecasted Market Size by Type (2021-2026)

5 Urothelial Cancer Drugs Breakdown Data by Application (2015-2026)
5.1 Global Urothelial Cancer Drugs Historic Market Size by Application (2015-2020)
5.2 Global Urothelial Cancer Drugs Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Urothelial Cancer Drugs Market Size (2015-2026)
6.2 North America Urothelial Cancer Drugs Market Size by Type (2015-2020)
6.3 North America Urothelial Cancer Drugs Market Size by Application (2015-2020)
6.4 North America Urothelial Cancer Drugs Market Size by Country (2015-2020)
6.4.1 United States
6.4.2 Canada

7 Europe
7.1 Europe Urothelial Cancer Drugs Market Size (2015-2026)
7.2 Europe Urothelial Cancer Drugs Market Size by Type (2015-2020)
7.3 Europe Urothelial Cancer Drugs Market Size by Application (2015-2020)
7.4 Europe Urothelial Cancer Drugs Market Size by Country (2015-2020)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
7.4.6 Nordic
7.4.7 Rest of Europe

8 China
8.1 China Urothelial Cancer Drugs Market Size (2015-2026)
8.2 China Urothelial Cancer Drugs Market Size by Type (2015-2020)
8.3 China Urothelial Cancer Drugs Market Size by Application (2015-2020)
8.4 China Urothelial Cancer Drugs Market Size by Region (2015-2020)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 Southeast Asia
8.4.5 India
8.4.6 Australia
8.4.7 Rest of Asia-Pacific

9 Japan
9.1 Japan Urothelial Cancer Drugs Market Size (2015-2026)
9.2 Japan Urothelial Cancer Drugs Market Size by Type (2015-2020)
9.3 Japan Urothelial Cancer Drugs Market Size by Application (2015-2020)
9.4 Japan Urothelial Cancer Drugs Market Size by Country (2015-2020)
9.4.1 Mexico
9.4.2 Brazil

10 Southeast Asia
10.1 Southeast Asia Urothelial Cancer Drugs Market Size (2015-2026)
10.2 Southeast Asia Urothelial Cancer Drugs Market Size by Type (2015-2020)
10.3 Southeast Asia Urothelial Cancer Drugs Market Size by Application (2015-2020)
10.4 Southeast Asia Urothelial Cancer Drugs Market Size by Country (2015-2020)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
10.4.4 Rest of Middle East & Africa

11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Urothelial Cancer Drugs Introduction
11.1.4 Roche Revenue in Urothelial Cancer Drugs Business (2015-2020))
11.1.5 Roche Recent Development
11.2 Merck
11.2.1 Merck Company Details
11.2.2 Merck Business Overview
11.2.3 Merck Urothelial Cancer Drugs Introduction
11.2.4 Merck Revenue in Urothelial Cancer Drugs Business (2015-2020)
11.2.5 Merck Recent Development
11.3 Bristol-Myers Squibb
11.3.1 Bristol-Myers Squibb Company Details
11.3.2 Bristol-Myers Squibb Business Overview
11.3.3 Bristol-Myers Squibb Urothelial Cancer Drugs Introduction
11.3.4 Bristol-Myers Squibb Revenue in Urothelial Cancer Drugs Business (2015-2020)
11.3.5 Bristol-Myers Squibb Recent Development
11.4 AstraZeneca
11.4.1 AstraZeneca Company Details
11.4.2 AstraZeneca Business Overview
11.4.3 AstraZeneca Urothelial Cancer Drugs Introduction
11.4.4 AstraZeneca Revenue in Urothelial Cancer Drugs Business (2015-2020)
11.4.5 AstraZeneca Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Details
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Urothelial Cancer Drugs Introduction
11.5.4 Pfizer Revenue in Urothelial Cancer Drugs Business (2015-2020)
11.5.5 Pfizer Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
  • FORMAT: PDF
  • PUBLISHED DATE: Aug, 2020
  • NO OF PAGES: 128